Dr. Reddy's faces fraud probe after Q1 earnings drop
pre-market1 source ↓written by the desknot a recommendation
- for semaglutide batch
- ₹2.4 billion provision
- in stock price
- 9.4% decline
Dr. Reddy's Laboratories is under investigation by Pomerantz LLP for potential securities fraud following its Q1 fiscal 2027 earnings, which reported EPS of $0.06. The results were adversely affected by a ₹2.4 billion provision for semaglutide batch issues, contributing to a 9.4% decline in stock price. This probe may impact investor confidence significantly.
Not investment advice. For informational purposes only.